JOGC

The Fetal Safety of Statins: A Systematic Review and Meta-Analysis

      Abstract

      Although an initial case series suggested that use of statins in pregnancy carried teratogenic risk, a recent meta-analysis of controlled observational studies has failed to corroborate this. A large number of potentially beneficial uses of statins in pregnant women have prompted a new evaluation of the risk-benefit ratio of these agents in pregnancy.

      Résumé

      Bien qu’une série de cas initiale ait laissé entendre que l’utilisation de statines pendant la grossesse donnait lieu à des risques tératogènes, une récente méta-analyse d’études observationnelles comparatives n’est pas parvenue à corroborer de tels résultats. Puisque les statines comptent un grand nombre d’utilisations potentiellement bénéfiques chez les femmes enceintes, une nouvelle évaluation du rapport risques-avantages de ces agents pendant la grossesse a été mise en œuvre.

      Key Words

      To read this article in full you will need to make a payment

      REFERENCES

        • Zarek J.
        • Delano K.E.
        • Nickel C.
        • Laskin C.
        • Koren K.
        Are statins teratogenic in humans? Addressing the safety of statins in light of potential benefits during pregnancy.
        Exp Rev Obstet Gynecol. 2013; 8: 513
        • Koren G.
        • Pastuszak A.
        • Ito S.
        Drugs in pregnancy.
        N Engl J Med. 1998; 338: 1128-1137
        • Sokalska A.
        • Wong D.H.
        • Cress A.
        • Piotrowski P.C.
        • Rzepczynska I.
        • Villanueva J.
        • et al.
        Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells.
        J Clin Endocrinol Metab. 2010; 95: 3453-3459
        • Sokalska A.
        • Cress A.
        • Bruner-Tran K.L.
        • Osteen K.G.
        • Taylor H.S.
        • Ortega I.
        • et al.
        Simvastatin decreases invasiveness of human endometrial stromal cells.
        Biol Reprod. 2012; 12: 1-6
        • Bruner-Tran K.L.
        • Osteen K.G.
        • Duleba A.J.
        Simvastatin protects against the development of endometriosis in a nude mouse model.
        J Clin Endocrinol Metabol. 2009; 94: 2489-2494
        • Oktem M.
        • Esinler I.
        • Eroglu D.
        • Haberal N.
        • Bayraktar N.
        • Zeyneloglu H.B.
        High-dose atorvastatin causes regression of endometriotic implants: a rat model.
        Hum Reprod. 2007; 22: 1474-1480
        • Banaszewska B.
        • Pawelczyk L.
        • Spaczynski R.Z.
        • Duleba A.J.
        Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
        J Clin Endocrinol Metab. 2011; 96: 3493-3501
        • Rashidi B.
        • Abediasl J.
        • Tehraninejad E.
        • Rahmanpour H.
        • Sills E.S.
        Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial.
        J Investig Med. 2011; 59: 912-916
        • Sathyapalan T.
        • Smith K.A.
        • Coady A.M.
        • Kilpatrick E.S.
        • Atkin S.L.
        Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
        Ann Clin Biochem. 2012; 49: 80-85
        • Rashidi B.
        • Abediasl J.
        • Tehraninejad E.
        • Rahmanpour H.
        • Sills E.S.
        Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial.
        J Investig Med. 2011; 59: 912-916
        • Raja-Khan N.
        • Kunselman A.R.
        • Hogeman C.S.
        • Stetter C.M.
        • Demers L.M.
        • Legro R.S.
        Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.
        Fertil Steril. 2011; 95: 1849-1852
        • Redecha P.
        • van Rooijen N.
        • Torry D.
        • Girardi G.
        Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.
        Blood. 2009; 113: 4101-4109
        • Kumasawa K.
        • Ikawa M.
        • Kidoya H.
        • Hasuwa H.
        • Saito-Fujita T.
        • Morioka Y.
        • et al.
        Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.
        Proc Natl Acad Sci. 2011; 108: 1451-1455
        • Singh J.
        • Ahmed A.
        • Girardi G.
        Role of complement component C1q in the onset of preeclampsia in mice.
        Hypertension. 2011; 58: 716-724
        • Minsker D.H.
        • MacDonald J.S.
        • Robertson R.T.
        • Bokelman D.L.
        Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase.
        Teratology. 1983; 28: 449-456
        • Lankas G.R.
        • Cukierski M.A.
        • Wise L.D.
        The role of maternal toxicity in lovastatin-induced developmental toxicity.
        Birth Defects Res B Dev Reprod Toxicol. 2004; 71: 111-123
        • Wise L.D.
        • Cukierski M.A.
        • Lankas G.R.
        • Skiles G.L.
        The predominant role of maternal toxicity in lovastatin-induced developmental toxicity.
        Teratology. 2000; 61: 444
      1. Lescol, Product Information. Novartis Pharmaceuticals Corp, East Hanover, NJ2012
      2. Zocor, Product Information. Merck & Co. Inc., Whitehouse Station, NJ2012
        • Edison R.J.
        • Muenke M.
        Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins.
        Am J Med Genet A. 2004; 131: 287-298
        • Gibb H.
        • Scialli A.R.
        Statin drugs and congenital anomalies.
        Am J Med Genet A. 2005; 135: 230-231
        • Bar-Oz B.
        • Moretti M.E.
        • Mareels G.
        • Van Tittelboom T.
        • Koren G.
        Reporting bias in retrospective ascertainment of drug-induced embryopathy.
        Lancet. 1999; 354: 1700-1701
        • Ofori B.
        • Rey E.
        • Berard A.
        Risk of congenital anomalies in pregnant users of statin drugs.
        Br J Clin Pharmacol. 2007; 64: 496-509
        • Taguchi N.
        • Rubin E.T.
        • Hosokawa A.
        • Choi J.
        • Ying A.Y.
        • Moretti M.E.
        • et al.
        Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes.
        Reprod Toxicol. 2008; 26: 175-177
        • McGrogan A.
        • Snowball J.
        • de Vries C.S.
        Statins and pregnancy outcomes: a cohort study in the GPRD.
        Pharmacoepidemiol Drug Saf. 2009; 18: S75-S76
        • Colvin L.
        • Slack-Smith L.
        • Stanley F.J.
        • Bower C.
        Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens.
        Pharmacoepidemiol Drug Saf. 2010; 19: 1137-1150
        • Paulus W.E.
        • Schloemp S.
        • Stoz F.
        Statin treatment in hypercholesterolemic mothers during early pregnancy.
        Geburtshilfe Frauenheilkd. 2008; 68: S130
        • Winterfeld U.
        • Allignol A.
        • Panchaud A.
        • Rothuizen L.E.
        • Merlob P.
        • Cuppers-Maarschalkerweerd B.
        • et al.
        Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
        BJOG. 2013; 120: 463-471
      3. ISRCTN Register. Statins to ameliorate early onset pre-eclampsia. Available at: http://www.controlled-trials.com/ISRCTN23410175. Accessed March 12, 2014.

      4. Clinical Trials.gov. Pravastatin for prevention of preeclampsia. Available at: http://clinicaltrials.gov/ct2/show/NCT01717586. Accessed March 12, 2014.